Apis Capital Advisors’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Apis Capital Advisors’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-214,000	Closed	-$4.34M	–	31
2022 Q4	$4.34M	Buy	214,000 +10,000	+5%	+$153K	5.03%	7
2022 Q3	$2.19M	Buy	204,000 +8,000	+4%	+$90.7K	3.29%	10
2022 Q2	$2.35M	Buy	196,000 +84,000	+75%	+$1.35M	2.65%	15
2022 Q1	$2.4M	Buy	112,000 +2,000	+2%	+$53K	2.9%	13
2021 Q4	$3.7M	Buy	110,000 +8,000	+8%	+$223K	4.1%	11
2021 Q3	$2.63M	Buy	102,000 +18,000	+21%	+$322K	2.5%	18
2021 Q2	$1.12M	Buy	84,000 +4,000	+5%	+$49.4K	0.97%	24
2021 Q1	$850K	Buy	80,000 +16,000	+25%	+$183K	0.77%	31
2020 Q4	$514K	Buy	+64,000	New	+$504K	0.5%	34
2019 Q3	$256K	Buy	+17,000	New	+$237K	0.4%	27

Apis Capital Advisors's OPNT Position: Q1 2023 in Review

Apis Capital Advisors sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 214,000 shares — an estimated $4.34M sold.

Apis Capital Advisors first reported a position in OPNT in Q3 2019 and held it in 10 quarters. The position peaked at $4.34M in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Apis Capital Advisors reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Apis Capital Advisors sold 214,000 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $4.34M.
Apis Capital Advisors first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
Apis Capital Advisors's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $4.34M in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Apis Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.